909 related articles for article (PubMed ID: 8635127)
21. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
Hurd TC; Sait S; Kohga S; Winston J; Martinick M; Saxena R; Lankes H; Markus G; Harvey S; Gibbs JF
Ann Surg Oncol; 2007 Nov; 14(11):3117-24. PubMed ID: 17701256
[TBL] [Abstract][Full Text] [Related]
24. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
[TBL] [Abstract][Full Text] [Related]
25. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints.
Busso N; Péclat V; So A; Sappino AP
Ann Rheum Dis; 1997 Sep; 56(9):550-7. PubMed ID: 9370880
[TBL] [Abstract][Full Text] [Related]
27. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels.
Del Vecchio S; Stoppelli MP; Carriero MV; Fonti R; Massa O; Li PY; Botti G; Cerra M; D'Aiuto G; Esposito G
Cancer Res; 1993 Jul; 53(13):3198-206. PubMed ID: 7686450
[TBL] [Abstract][Full Text] [Related]
28. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
Andres SA; Edwards AB; Wittliff JL
J Clin Lab Anal; 2012 Feb; 26(2):93-103. PubMed ID: 22467324
[TBL] [Abstract][Full Text] [Related]
29. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
[TBL] [Abstract][Full Text] [Related]
30. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
31. Dissemination risk index based on plasminogen activator system components in primary breast cancer.
Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
J Clin Oncol; 1999 Oct; 17(10):3048-57. PubMed ID: 10506599
[TBL] [Abstract][Full Text] [Related]
32. Vitamin D3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture.
Barbosa EM; Nonogaki S; Katayama ML; Folgueira MA; Alves VF; Brentani MM
Virchows Arch; 2004 Feb; 444(2):175-82. PubMed ID: 14652754
[TBL] [Abstract][Full Text] [Related]
33. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
34. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1).
Borgfeldt C; Hansson SR; Gustavsson B; Måsbäck A; Casslén B
Int J Cancer; 2001 May; 92(4):497-502. PubMed ID: 11304683
[TBL] [Abstract][Full Text] [Related]
35. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
36. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
37. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
38. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
39. Correlation of tissue and blood plasminogen activation system in breast cancer.
Rha SY; Yang WI; Gong SJ; Kim JJ; Yoo NC; Roh JK; Min JS; Lee KS; Kim BS; Chung HC
Cancer Lett; 2000 Mar; 150(2):137-45. PubMed ID: 10704735
[TBL] [Abstract][Full Text] [Related]
40. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
Kobayashi H; Fujishiro S; Terao T
Cancer Res; 1994 Dec; 54(24):6539-48. PubMed ID: 7987854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
